
Leen Kawas, Alzheimer’s CEO who resigned in data manipulation scandal, returns to launch investment firm with billionaire
Leen Kawas, the startup founder and CEO who united investors behind a darkhorse approach to treating Alzheimer’s before resigning last year in a data manipulation scandal, is back.
Kawas and billionaire private equity investor Richard Kayne announced on Friday the launch of Propel Bio, a new investment firm focused on “companies at various stages across the life science space.”
The pair offered few other details about the new firm, and a spokesperson said that neither would speak on the record or comment beyond the release “to comply with SEC regulations.” An SEC filing Friday indicated the company planned to raise $150 million, but did not list any funds raised to date.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.